$352.48−0.83% 1DFinazon · prior-day close · Aug 18, 2026
Price · Chart
Our own end-of-day closes60 sessions
$400$25022 May18 Aug
The line runs $287.85 on 22 May through $352.48 on 18 August, on a scale from $250 to $400. Days the market did not trade hold the previous close, flat.
The chart above plots the price of BIO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 60 sessions over that window: $287.85 on 22 May 2026 through $352.48 on 18 August 2026.
Market cap$9.5B
52-week range$242 – $362.31
Avg volume63.3K
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 19, 2026
Filings 4 sets
BIO reported financials
SEC EDGAR XBRL
BIO reported revenue of $2.6B for the fiscal year ended 31 Dec 2025. Net income over the same period was $759.9M.
FigureReportedPeriod
Revenue
$2.6B
31 Dec 2025 fiscal year
Net income
$759.9M
31 Dec 2025 fiscal year
Diluted EPS
$27.85
31 Dec 2025 fiscal year
Total assets
$10.3B
30 Jun 2026 at period end
Total equity
$7.2B
30 Jun 2026 at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
BIO earnings
SEC EDGAR
DatePeriodEPSRevenue
30 Jun 2026Q2 2026$13.85$651M
31 Mar 2026Q1 2026$-19.55$592M
31 Dec 2025FY 2025$27.85$2.58B
30 Sep 2025Q3 2025$-12.70$653M
30 Jun 2025Q2 2025$11.67$652M
31 Mar 2025Q1 2025$2.29$585M
31 Dec 2024FY 2025$-25.57$2.57B
30 Sep 2024Q3 2024$23.34$650M
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
BIO institutional holders
SEC Form 13F
10 of the 45 institutional funds we track reported a BIO position for the quarter ended 30 Jun 2026 — a combined $155.7M; the latest of those filings landed 14 Aug 2026.